Roth Capital Upgrades Nuwellis (NASDAQ:NUWE) to “Strong-Buy”

Nuwellis (NASDAQ:NUWE) was upgraded by equities research analysts at Roth Capital to a “strong-buy” rating in a report released on Monday, Zacks.com reports.

Separately, Roth Mkm assumed coverage on Nuwellis in a report on Monday. They issued a “buy” rating and a $17.00 price target for the company.

Nuwellis Trading Down 2.1 %

Nuwellis stock opened at $2.78 on Monday. The stock has a 50-day moving average price of $5.93 and a 200 day moving average price of $11.36. Nuwellis has a 52 week low of $2.19 and a 52 week high of $92.75. The stock has a market cap of $1.81 million, a PE ratio of -0.01 and a beta of 0.44.

Nuwellis (NASDAQ:NUWE) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($21.00) EPS for the quarter. The firm had revenue of $1.86 million for the quarter. Nuwellis had a negative return on equity of 316.90% and a negative net margin of 202.97%.

Nuwellis Company Profile

Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.